Recent findings concerning thiazolidinediones in the treatment of diabetes

Expert Opinion on Investigational Drugs
Guenther Boden, Meijuan Zhang

Abstract

Thiazolidinediones (TZDs) are peroxisomal proliferator-activated receptor (PPAR)-gamma agonists. They increase insulin action through several mechanisms including: stimulation of the expression of genes that increase fat oxidation and lower plasma free fatty acid levels; increased expression, synthesis and release of adiponectin; and stimulation of adipocyte differentiation resulting in more and smaller fat cells. TZDs lower blood sugar comparably to sulfonylureas and metformin. The clinical use of TZDs is limited due to the long duration of time required before they reach their full blood sugar-lowering action (3-4 months) and adverse effects such as fluid retention, resulting in excessive weight gain and occasionally in peripheral and/or pulmonary oedema and congestive heart failure. Troglitazone, a TZD that has since been removed from the market because of hepatoxicity, has been demonstrated to decrease the progression from normal or impaired glucose tolerance to overt Type 2 diabetes mellitus. Pioglitazone, another TZD, marginally decreased the incidence of cardiovascular complications in patients with Type 2 diabetes mellitus (PROactive trial). Other, as yet, unapproved uses of TZDs include: non-alcoholic fatty liver disea...Continue Reading

References

May 1, 1988·Japanese Journal of Medicine·H NomuraM Goto
May 15, 1994·Genes & Development·P TontonozB M Spiegelman
Apr 16, 1998·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·F H LuyckxP J Lefèbvre
Aug 26, 1998·The Journal of Clinical Endocrinology and Metabolism·J YipG M Reaven
Oct 22, 1998·La Revue du praticien·P Giral
Nov 24, 1999·The American Journal of Medicine·G MarchesiniN Melchionda
Jan 22, 2000·Annals of Internal Medicine·S BellentaniC Tiribelli
Jun 10, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·K HottaY Matsuzawa
Aug 6, 2000·Annals of Internal Medicine·E AriogluS I Taylor
Nov 30, 2000·Biochemical and Biophysical Research Communications·J SakamotoH Sawada
Apr 11, 2001·Obstetrics and Gynecology Clinics of North America·M J Iuorno, J E Nestler
Jun 8, 2001·Annual Review of Biochemistry·T M WillsonS A Kliewer
Aug 8, 2001·The Journal of Clinical Investigation·J K KimG I Shulman
Jan 31, 2002·Annual Review of Medicine·Joel Berger, David E Moller
Apr 19, 2002·The New England Journal of Medicine·Paul Angulo
Jun 7, 2002·The Journal of Clinical Endocrinology and Metabolism·Yoshinori MiyazakiRalph A DeFronzo
Oct 25, 2002·The New England Journal of Medicine·David M Nathan
Feb 8, 2003·The Journal of Clinical Endocrinology and Metabolism·Giancarlo ParadisiAlain D Baron

❮ Previous
Next ❯

Citations

Feb 8, 2011·Current Opinion in Endocrinology, Diabetes, and Obesity·Guenther Boden
Oct 11, 2007·Diabetes, Obesity & Metabolism·O SchnellUNKNOWN Acarbose-Insulin Combination Study Group
Mar 19, 2008·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·David Wright, Lindsey Sutherland
Mar 25, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yehuda KamariEhud Grossman
Aug 24, 2010·Vascular Health and Risk Management·James E Foley, Jens Jordan
Sep 4, 2013·Pflügers Archiv : European journal of physiology·Jean-Louis GuéantRosa-Maria Guéant-Rodriguez
Jul 16, 2014·Pathology, Research and Practice·Bianka BojkováKarol Kajo
Sep 12, 2008·PPAR Research·Tianxin Yang, Sunhapas Soodvilai
Jul 25, 2006·Expert Opinion on Drug Metabolism & Toxicology·Kenneth L Hastings
Apr 7, 2010·Expert Opinion on Investigational Drugs·Lalit S DoshiKumar V S Nemmani
Nov 27, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kjeld Hermansen, Lene S Mortensen
Dec 26, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wai Kwan LauTengku Sifzizul Tengku Muhammad
Jan 9, 2013·Bioorganic & Medicinal Chemistry·Joshua P TaygerlyMotonao Nakamura
Nov 7, 2015·Current Therapeutic Research, Clinical and Experimental·Sudha S ShankarDavid E Kelley
May 19, 2009·Journal of Neuroimmunology·Claudia C KaiserDouglas L Feinstein
May 12, 2009·Journal of Ethnopharmacology·Hao-Shu WuQiao-Jun He
May 20, 2009·Journal of Molecular Biology·Alykhan MotaniYang Li
Sep 9, 2008·Endocrinology and Metabolism Clinics of North America·Guenther Boden
Mar 12, 2008·Liver International : Official Journal of the International Association for the Study of the Liver·Jill K J GaidosArun J Sanyal
Sep 10, 2014·Diabetes, Obesity & Metabolism·B WesselsJ J Prompers
Dec 13, 2006·Bioorganic & Medicinal Chemistry Letters·Hee Oon HanGeun Tae Kim
Aug 25, 2016·BMC Complementary and Alternative Medicine·Chao-Wei HuangTang-Long Shen
Feb 3, 2007·The Diabetes Educator·Catherine L Martin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alagille Syndrome

Alagille syndrome is a multi-system genetic disorder that can affect the liver, heart, and other parts of the body. It’s characterization includes heart problems, liver damage, jaundice, and xanthomas. Here is the latest research.

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.